Article info
Benefits to nonparticipants
Paper
The social value of candidate HIV cures: actualism versus possibilism
- Correspondence to Dr Nicholas Greig Evans, Department of Medical Ethics and Health Policy, University of Pennsylvania, 423 Guardian Drive, Floor 14, Philadelphia, PA 19104, USA Department of Philosophy University of Massachusetts, Lowell, 883 Broadway Ave, Lowell, MA 01854 nicholas_evans{at}uml.edu
Citation
The social value of candidate HIV cures: actualism versus possibilism
Publication history
- Received January 30, 2016
- Revised May 20, 2016
- Accepted June 15, 2016
- First published July 8, 2016.
Online issue publication
February 16, 2017
Article Versions
- Previous version (25 January 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- When to start paediatric testing of the adult HIV cure research agenda?
- Why cure, why now?
- Reconceptualising risk–benefit analyses: the case of HIV cure research
- First-in-human HIV-remission studies: reducing and justifying risk
- The Ebola clinical trials: a precedent for research ethics in disasters
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- How to keep high-risk studies ethical: classifying candidate solutions
- Cancer immunotherapy in adult patients with HIV
- Factors associated with attitudes towards HIV cure research among transgender women and travestis: a cross-sectional survey in São Paulo, Brazil
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia